BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1477 related articles for article (PubMed ID: 17296569)

  • 1. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
    Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
    Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
    Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
    Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
    Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
    J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism.
    Kovacs MJ; Kahn SR; Wells PS; Anderson DA; Chagnon I; LE Gal G; Solymoss S; Crowther M; Perrier A; Ramsay T; Betancourt MT; White RH; Vickars L; Rodger MA
    J Thromb Haemost; 2010 Sep; 8(9):1926-32. PubMed ID: 20561184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
    Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
    Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis.
    Prandoni P; Vedovetto V; Ciammaichella M; Bucherini E; Corradini S; Enea I; Cosmi B; Mumoli N; Visonà A; Barillari G; Bova C; Quintavalla R; Zanatta N; Pedrini S; Villalta S; Camporese G; Testa S; Parisi R; Becattini C; Cuppini S; Pengo V; Palareti G;
    Thromb Res; 2017 Jun; 154():35-41. PubMed ID: 28407492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thirteen-year trend in the persistence with vitamin K antagonists for venous thromboembolism in the UK: a cohort study.
    Martinez C; Katholing A; Folkerts K; Rietbrock S
    Curr Med Res Opin; 2018 Nov; 34(11):1985-1990. PubMed ID: 29798688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.
    Prandoni P; Prins MH; Lensing AW; Ghirarduzzi A; Ageno W; Imberti D; Scannapieco G; Ambrosio GB; Pesavento R; Cuppini S; Quintavalla R; Agnelli G;
    Ann Intern Med; 2009 May; 150(9):577-85. PubMed ID: 19414836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
    Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
    Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
    Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
    J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
    Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
    Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
    Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
    BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.
    Hansson PO; Sörbo J; Eriksson H
    Arch Intern Med; 2000 Mar; 160(6):769-74. PubMed ID: 10737276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.